ianalumabSRI-6SRI-4systemic lupus erythematosusSLENCT03656562
…ge: 17W–187W). At W28, higher proportions of patients receiving ianalumab achieved SRI-4 (70.6%), SRI-6 (50.0%), LLDAS (17.6%), DORIS (11…
10,506articles mentioning drugs
58,393drug mentions
9,496distinct drugs extracted
0%of mentions human-reviewed
All extracted drugs
Showing 541–600 of 9,496, ordered by supporting articles. Choose a drug to see its evidence.
N-Acetyl Cysteine7PPIs7Streptozotocin7fondaparinux7high-dose corticosteroids7hydroxyurea7naltrexone7tyrosine kinase inhibitors7vaccines7SGLT-2i6Glipizide6BLV6Varenicline6Camrelizumab6Cancer Drugs6Benzene6Doxy-PEP6SGLT-2is6Aprepitant6DEX6Dostarlimab6T-DXd6Azacitidine6Esketamine6NAC6Fidaxomicin6ITM6Minocycline6N-acetylcysteine6pMDIs6NBCA6Clofazimine6Filgotinib6Ravulizumab6Atomoxetine6Methylphenidate6amoxicillin-clavulanate6Acetylcysteine6Triamcinolone6anti-PD16Nitrous oxide6Octreotide6injectate6IL-1β6Lenalidomide6OAC6Venetoclax6antihypertensive drugs6n-BCA6Anti-TNF6Golimumab6Placebo6aripiprazole6b/tsDMARDs6Lansoprazole6MDPV6Mitomycin C6Nalbuphine6PCSK9 inhibitors6Sodium-Glucose Co-Transporter 2 Inhibitors6
Articles mentioning drugs
10,506 articles · page 98 of 876ANIprednisoneSLESLE-DASKikuchi disease
…loading dose. In addition to corticosteroids and antimalarials, ANI was administered in many cases concomitantly with other immunom…
HydroxychloroquineHCQSLEsystemic lupus erythematosusCKDtertiary referral center
…Objectives Hydroxychloroquine (HCQ) is a cornerstone therapy in systemic lupus erythematosus …
voclosporinprednisolonelupus nephritisKDIGO 2024
…jectives Following the successful AURORA-1 and AURORA-2 trials, voclosporin was incorporated into the KDIGO 2024 clinical guidelines for th…
Dapirolizumab pegolDZPprednisoneSLESLE-specificLupus
… including fatigue, musculoskeletal pain and morning stiffness. Dapirolizumab pegol (DZP) is a novel CD40L inhibitor with broad modulatory effects …
CannabisUK BiobankCanUDdementia
…up is warranted to confirm these findings.Clinical implications Cannabis use in older adults does not appear linked to faster cognitive …
camrelizumabgemcitabinecisplatinhigh risk nasopharyngeal carcinoma
…se events (grade 3 or 4) occurred in 19 patients (10.2%) in the camrelizumab group.Conclusion The addition of camrelizumab to concurrent che…
azithromycinAzithromycin-resistantchronic lung disease of prematurity
…ably prevalent in the placebo group, with minimal increase with azithromycin treatment, suggesting that, regardless of the additional use of…
ranibizumabavacincaptad pegolACPgeographic atrophynAMDneovascular age-related macular degenerationNCT00709527
…herapy for geographic atrophy, administered in combination with ranibizumab, an approved therapy for neovascular age-related macular degene…
ticagrelorprasugrelclopidogrelaspirincoronary heart diseaseCHDWanfangacute coronary syndromeChina National Knowledge Infrastructure
… P2Y12 receptor antagonist), mainly with low-dose prasugrel and ticagrelor. Off-label low-dose antiplatelet agents significantly reduced m…
ROSE12ipilimumabsolid tumors
… while reducing binding to inhibitory FcγRIIb. In mouse models, ROSE12 monotherapy significantly inhibited tumor growth in both conven…
IPTp-SPsulfadoxine-pyrimethaminemalariaANC
…ers interviewed in Mali (44) and Burkina Faso (41) thought that IPTp-SP delivery through SMC increased ANC attendance and reduced malar…